Seroprevalence of diphtheria toxoid IgG antibodies in children, adolescents and adults in Poland

BMC Infectious Diseases

Marek Jagielski¹  Natalia Rokosz¹  Waldemar Rastawicki¹  Aleksandra A Zasada¹ 

[1] Department of Bacteriology, National Institute of Public Health – National Institute of Hygiene, Chocimska 24, Warsaw 00-791, Poland

关键词: Vaccination;    Diphtheria toxin;    IgG antibodies;    Diphtheria;   

Others  :  1145368
DOI  :  10.1186/1471-2334-13-551

 received in 2013-05-14, accepted in 2013-11-14,  发布年份 2013

【 摘 要 】

Background

Recommendations for diphtheria immunization are to apply an effective primary immunization in infancy and to maintain immunity throughout life. Immunity against diphtheria depends primarily on antibody to the diphtheria toxin. This study evaluated the seroprevalence of IgG diphtheria antitoxin in sera of healthy children, adolescents and adults in Poland.

Methods

A total of 1387 serum samples collected between 2010 and 2012 from individuals with ages ranging from 1 month to 85 years were investigated. Antibody concentrations were measured with an enzyme-linked immunosorbent assay (Anti-Diphtheria Toxoid ELISA IgG, Euroimmun, Germany).

Results

The results showed that among 1387 individuals examined, 547 (39.4%) had anti-diphtheria toxoid IgG antibody levels below 0.1 IU/ml (36.9% ≤18 years and 40.5% >18 years old, respectively). The 212 (50.8%) children and 542 (55.9%) adults showed only basic protection (0.1-1.0 IU/ml) and need immediate booster. High levels of anti-diphtheria toxoid IgG antibodies (>1.0 IU/ml) were found more often in children and adolescent (12.2%) than in adults (3.6%) and this was statistically significant (P < 0.05). The proportion of seronegatives (< 0.1 IU/ml) in children below 2 years old, adolescents and young adults to 25 years old decreased from 53.5% to 17.4%. However, in older individuals the seronegative proportion tended to increase with age, from 22.7% in adults (26–30 years old) to 67.1% in subjects > 60 years old. Characteristically, in individuals > 40 years old high levels of anti-diphtheria toxoid IgG antibodies (>1.0 IU/ml) were not seen. There were no statistically significant differences in results in relation to gender.

Conclusions

The present study showed inadequate immunity levels to diphtheria amongst the Polish population, especially in adults > 40 years old and children ≤ 2 years old. To prevent reemergence of diphtheria an information campaign reminding people about recommendations concerning diphtheria booster vaccination in adults should be conducted. Moreover, the immunogenicity of the DTP vaccine used in Poland should be verified.

【 授权许可】

   
2013 Zasada et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Wagner KS, White JM, Lucenko I, Mercer D, Crowcroft NS, Neal S, Efstratiou A, And on behalf of the Diphtheria Surveillance Network: Diphtheria in the postepidemic period, Europe, 2000–2009. Emerg Infect Dis 2012, 18:217-225.
• [2]Tiwari TSP: Diphtheria. In CDC Health Information for International Travel 2012 – Yellow Book. Edited by Brunette GW. New York: Oxford University Press; 2012:162-164. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/diphtheria.htm webcite
• [3]Walory J, Grzesiowski P, Hryniewicz W: The prevalence of diphtheria immunity in healthy population in Poland. Epidemiol Infect 2001, 126:225-230.
• [4]Sheifele DW, Ochnio JJ: The immunological basis for immunization series. Geneva: World Health Organization; 2009. [Module 2: diphtheria update 2009]
• [5]Gałązka A: The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 2000, 181(Suppl 1):S2-S9.
• [6]Gałązka AM, Robertson SE, Oblapenko P: Resurgence of diphtheria. Eur J Epidemiol 1995, 11:95-105.
• [7]De Zoysa A, Efstratiou A: Eight international meeting of the European laboratory working group on diphtheria and the diphtheria surveillance network – June 2004: progress is needed to sustain control of diphtheria in European Region. Eurosurveill 2004, 9:489.
• [8]Bonmarin I, Guiso N, Le Fleche-Mateos A, Patey O, Grimont PAD, Levy-Bruhl D: Diphtheria: a zoonotic disease in France? Vaccine 2009, 27:4196-4200.
• [9]Taylor J, Saveeda-Campos M, Harwood D, Pritchard G, Raphaely N, Kapadia S, Efstratiou A, White J, Balasegaram S: Toxigenic Corynebacterium ulcerans infection in veterinary student in London, United Kingdom, May 2010. Eurosurveill 2010, 15:19634.
• [10]NIPH-NIH: Reports on cases of infectious diseases and poisonings in Poland. http://www.pzh.gov.pl/oldpage/epimeld/index_a.html#01 webcite
• [11]Zasada AA, Rastawicki W, Śmietańska K, Rokosz N, Jagielski M: Comparison of seven commercial enzyme-linked immunosorbent assays for the detection of anti-diphtheria toxin antibodies. Eur J Clin Microbiol Infect Dis 2013, 32:891-897.
• [12]Begg N: Diphtheria: manual for the management and control of diphtheria in the European region. Copenhagen: WHO; 1994.
• [13]CDC: Diphtheria. In Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th edition. Edited by Atkinson W, Wolfe S, Hamborsky J. Washington DC: Public Health Foundation; 2012:75-85.
• [14]Di Giovine P, Kafatos G, Nardone A, Andrews N, Olander RM, Alfarone G, Broughton K, Cohen D, Kriz B, Mikova I, O’Flanagan D, Schneider F, Selga I, Valinskz L, Velicko I, Karacs I, Pebodz R, Von Hunolstein C: Comparative seroepidemiology of diphtheriae in six European countries and Israel. Epidemiol Infect 2013, 141:132-142.
• [15]Ohuabunwo C, Perevoscikovs J, Griskevica A, Gargiullo P, Brilla A, Viksna L, Glismann S, Wharton M, Vitek C: Respiratory diphtheria among highly vaccinated military trainees in Latvia: improved protection from DT compared with Td booster vaccination. Scand J Infec Dis 2005, 37:813-820.
• [16]Edmunds WJ, Pebody RG, Aggerback H, Baron S, Berbers G, Conyn-van Spaendonck MAE, Hallander HO, Olander R, Maple PAC, Melker HE, Olin P, Fievret-Groyne F, Rota C, Salmaso S, Tischer A, Von-Honulstein C, Miller E: The sero-epidemiology of diphtheria in Western Europe. Epidemiol Infect 2000, 125:113-125.
• [17]Chironna M, Germinario C, Lopalco PL, Carrozzini F, Barbuti S, Quarto M: Immunity to diphtheria among refugees in southern Italy. Vaccine 2003, 21:3157-3161.
• [18]Patel SS, Wagstaff AJ: A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection. Drugs 1996, 52:254-275.
• [19]Matheson AJ, Goa KL: Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection. Paediatr Drugs 2000, 2:139-159.
• [20]Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, Englund JA, Steinhoff MC, Deforest A, Meade BD: A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997, 100:722-788.
• [21]Marcinak JF, Ward M, Frank AL, Boyer KM, Froeschle JE, Hosbach PH 4th: Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children. Am J Dis Child 1993, 147:290-294.
• [22]Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, Blackwelder WC, Jansen DL, Meade BD: Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 2000, 105:1-8.
• [23]Cm M, Blumberg DA, Cherry JD, Reisinger KS, Blatter MM, Blumer JL, Dekker CL, Stout MG, Christenson PD: Comparison of acellular and whole-cell pertussis-component DTP vaccines, A multicenter double-blind study in 4- to 6-year-old children. Am J Dis Child 1990, 144:41-45.
• [24]Launay O, Toneatti C, Bernede C, Njamkepo E, Petitprez K, Leblond A, Larnaudine S, Goujon C, Ungeheuer M-N, Ajana F, Raccurt C, Beytout J, Chidiac C, Bouhour D, Guillemot D, Guiso N: Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccin 2009, 5:341-346.
• [25]Pachon I, Amela C, De Ory F: Age-specific seroprevalence of poliomyelitis, diphtheria and tetanus antibodies in Spain. Epidemiol Infect 2002, 129:535-541.
• [26]Marlovits S, Stocker R, Efstatiou A, Broughton K, Kaider A, Vecsei V, Wiedermann G, Kollaritsch H: Seroprevalence of diphtheria immunity among injured adults in Austria. Vaccine 2001, 19:1061-1067.
• [27]De Melker HE, Berbers GAM, Nagelkerke NJD, Conyn-van Spaendonck MAE: Diphtheria antitoxin levels in the Netherlands: a population-based study. Emerg Infect Dis 1999, 5:694-700.
• [28]Aue A, Hennig H, Kruger S, Closius B, Kirchner H, Seyfarth M: Immunity against diphtheria and tetanus in German blood donors. Med Microbiol Immunol 2003, 192:93-97.
• [29]Mossong J, Putz L, Shkedy Z, Scheider F: Seroepidemiology of diphtheria and pertussis in Luxembourg in 2000. Epidemiol Infect 2006, 134:573-578.